Immune Pharmaceuticals is enrolling patients in a Phase I and II clinical trial that will determine the safety and efficacy levels of Ceplene as a treatment for Chronic Myelomonocytic Leukemia (CMML).
"Now that Cytovia has regained worldwide ownership of Ceplene following the transaction with Mylan, we have the opportunity to implement a comprehensive development and commercialization strategy for Ceplene,” Dr. Daniel Teper said in a statement. “Chronic Myelomonocytic Leukemia represents a new indication for Ceplene, which fits in well with our strategy to develop new indications beyond Acute Myeloid Leukemia (AML) and to generate new intellectual property covering Ceplene's use."
The trial will involve 15 adult patients with CMM who will receive Ceplene in conjunction with low-dose Proleukin.
"CMML cells exert immunosuppression that is targeted by Ceplene," Professor Kristoffer Hellstrand of the Institute of Biomedicine of the University of Gothenburg in Sweden, said in a statement. "By reducing immunosuppression, Ceplene improves the function of anti-leukemic immune cells, including T cells and natural killer cells."
The University of Gothenburg is providing funding for the study.